Table 5. Prediction model related to fatty liver progression.
| Variable | N | Model 1 * | Model 2 † | Model 3 § | Model 4 ¶ | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |||
| Before matching | All | |||||||||
| Control | 296 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||||
| Aromatase inhibitor | 199 | 1.331 (0.985–1.798) | 0.063 | 1.232 (0.902–1.682) | 0.190 | 1.191 (0.858–1.654) | 0.295 | 1.381 (0.806–2.367) | 0.239 | |
| Tamoxifen | 416 | 1.744 (1.361–2.234) | <0.001 | 1.882 (1.461–2.424) | <0.001 | 1.860 (1.416–2.444) | <0.001 | 1.859 (1.167–2.96) | 0.009 | |
| Fatty liver (-) at baseline | ||||||||||
| Control | 226 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||||
| Aromatase inhibitor | 128 | 1.389 (0.971–1.985) | 0.072 | 1.231 (0.848–1.788) | 0.274 | 1.100 (0.742–1.631) | 0.634 | 1.135 (0.597–2.156) | 0.699 | |
| Tamoxifen | 297 | 1.467 (1.103–1.952) | 0.009 | 1.665 (1.244–2.227) | 0.001 | 1.612 (1.172–2.217) | 0.003 | 1.511 (0.843–2.708) | 0.165 | |
| Fatty liver (+) at baseline | ||||||||||
| Control | 70 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||||
| Aromatase inhibitor | 71 | 1.514 (0.844–2.718) | 0.164 | 1.581 (0.87–2.871) | 0.133 | 1.749 (0.898–3.405) | 0.100 | 2.410 (0.666–8.722) | 0.180 | |
| Tamoxifen | 119 | 2.691 (1.61–4.497) | <0.001 | 2.672 (1.575–4.534) | <0.001 | 2.998 (1.646–5.462) | <0.001 | 3.668 (1.232–10.925) | 0.020 | |
| After matching | All | |||||||||
| Control | 256 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||||
| Tamoxifen | 256 | 1.636 (1.237–2.165) | 0.001 | 1.714 (1.293–2.271) | <0.001 | 1.773 (1.294–2.43) | <0.001 | 1.716 (0.98–3.005) | 0.059 | |
| Fatty liver (-) at baseline | ||||||||||
| Control | 202 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||||
| Tamoxifen | 186 | 1.481 (1.075–2.042) | 0.016 | 1.612 (1.166–2.23) | 0.004 | 1.590 (1.092–2.314) | 0.016 | 1.497 (0.745–3.007) | 0.257 | |
| Fatty liver (+) at baseline | ||||||||||
| Control | 54 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||||
| Tamoxifen | 70 | 2.241 (1.244–4.038) | 0.007 | 2.219 (1.226–4.015) | 0.008 | 2.907 (1.451–5.821) | 0.003 | 279.154 (2.887–26992.851) | 0.016 | |
Abbreviations: HR, hazard ratio; CI, confidence interval.
* Model 1: unadjusted.
† Model 2: adjusted for age, BMI, and underlying disease (diabetes, hypertension).
§ Model 3: Model 2 plus cancer-related factors (stage, pathology, lymph node metastasis).
¶ Model 4: Model 3 plus initial laboratory factors (FSH, platelet, AST, ALT, total bilirubin, total cholesterol, triglyceride, fasting blood glucose).